dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Castiglione, M. | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Castiglione, M. | en |
dc.date.accessioned | 2018-06-22T09:54:28Z | |
dc.date.available | 2018-06-22T09:54:28Z | |
dc.date.issued | 2009 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42368 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Europe | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Bleomycin | en |
dc.subject | Chlormethine | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Cytarabine | en |
dc.subject | Dacarbazine | en |
dc.subject | Dactinomycin | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Neoplasms | en |
dc.subject | Prednisone | en |
dc.subject | Procarbazine | en |
dc.subject | Vinblastine | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Mammography | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Follow up | en |
dc.subject | Priority journal | en |
dc.subject | Oxaliplatin | en |
dc.subject | Taxane derivative | en |
dc.subject | Treatment outcome | en |
dc.subject | Abortion | en |
dc.subject | Neoplastic | en |
dc.subject | Pregnancy complications | en |
dc.subject | Pregnancy | en |
dc.subject | Busulfan | en |
dc.subject | Melphalan | en |
dc.subject | Mercaptopurine | en |
dc.subject | Teratogenicity | en |
dc.subject | Unindexed drug | en |
dc.subject | Irinotecan | en |
dc.subject | Melanoma | en |
dc.subject | Oligohydramnios | en |
dc.subject | Trastuzumab | en |
dc.subject | Uterine cervix cancer | en |
dc.subject | Risk assessment | en |
dc.subject | Follow-up studies | en |
dc.subject | Drug megadose | en |
dc.subject | Cancer incidence | en |
dc.subject | Malignant neoplastic disease | en |
dc.subject | Nuclear magnetic resonance imaging | en |
dc.subject | Thorax radiography | en |
dc.subject | Alkylating agent | en |
dc.subject | Anthracycline derivative | en |
dc.subject | Ifosfamide | en |
dc.subject | Vinca alkaloid | en |
dc.subject | Health planning guidelines | en |
dc.subject | Medical | en |
dc.subject | Social support | en |
dc.subject | Societies | en |
dc.subject | Rituximab | en |
dc.subject | Lymphoma | en |
dc.subject | Fludarabine | en |
dc.subject | Chlorambucil | en |
dc.subject | Lymphocytopenia | en |
dc.subject | Radiation dose | en |
dc.subject | Thiotepa | en |
dc.subject | Infertility | en |
dc.subject | Cryopreservation | en |
dc.subject | Acute leukemia | en |
dc.subject | Pregnancy termination | en |
dc.subject | Fertility | en |
dc.subject | Gonadotoxicity | en |
dc.subject | Gynecologic disease | en |
dc.subject | Ionizing radiation | en |
dc.title | Cancer, fertility and pregnancy: ESMO Clinical Recommendations for diagnosis, treatment and follow-up | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdp166 | |
dc.description.volume | 20 | |
dc.description.issue | SUPPL. 4 | en |
dc.description.startingpage | iv178 | |
dc.description.endingpage | iv181 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |